Terns Pharmaceuticals Announces First Participant Dosed In Phase 1 Clinical Trial Of TERN-601 Oral GLP-1 Receptor Agonist For Treatment Of Obesity
Portfolio Pulse from Benzinga Newsdesk
Terns Pharmaceuticals has announced the first participant has been dosed in the Phase 1 clinical trial of TERN-601, an oral GLP-1R agonist for the treatment of obesity. The trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TERN-601 in healthy adults with obesity or overweight. The company anticipates 28-day proof of concept data in the second half of 2024. TERN-601 is part of Terns' obesity franchise, which also includes the TERN-600 series of GLP-1R agonists and the TERN-800 series of GIPR modulators.
November 02, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Terns Pharmaceuticals has initiated a Phase 1 clinical trial for TERN-601, a potential treatment for obesity. The trial's results, expected in 2H24, could impact the company's stock depending on the outcomes.
The initiation of a Phase 1 clinical trial is a significant step in the development of a new drug. However, the results of the trial, which are expected in the second half of 2024, will have a more direct impact on the company's stock. Positive results could boost the stock, while negative results could cause it to fall.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100